T. Rowe Price Associates
SYRS

T. Rowe Price Associates’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

T. Rowe Price Associates’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,550
Closed -$49K – 3072
2024
Q3 		$49K Hold
22,550
– – ﹤0.01% 2930
2024
Q2 		$117K Hold
22,550
– – ﹤0.01% 2726
2024
Q1 		$121K Hold
22,550
– – ﹤0.01% 2747
2023
Q4 		$176K Hold
22,550
– – ﹤0.01% 2586
2023
Q3 		$90K Hold
22,550
– – ﹤0.01% 2689
2023
Q2 		$72K Hold
22,550
– – ﹤0.01% 2754
2023
Q1 		$61K Buy
22,550
+10,400
+86% +$40.3K ﹤0.01% 2765
2022
Q4 		$44K Buy
+12,150
New +$52.7K ﹤0.01% 2828
2022
Q3 		– Sell
-8,092
Closed -$78K – 3049
2022
Q2 		$78K Buy
8,092
+4
+0% +$37 ﹤0.01% 2808
2022
Q1 		$96K Sell
8,088
-2,040
-20% -$36.5K ﹤0.01% 2853
2021
Q4 		$330K Buy
10,128
+5,220
+106% +$211K ﹤0.01% 2561
2021
Q3 		$219K Buy
+4,908
New +$240K ﹤0.01% 2692
2021
Q1 		– Sell
-4,759
Closed -$516K – 2876
2020
Q4 		$516K Buy
4,759
+629
+15% +$57.4K ﹤0.01% 2224
2020
Q3 		$365K Buy
4,130
+1,880
+84% +$214K ﹤0.01% 2216
2020
Q2 		$240K Sell
2,250
-6,455
-74% -$579K ﹤0.01% 2318
2020
Q1 		$516K Buy
8,705
+4,455
+105% +$302K ﹤0.01% 1978
2019
Q4 		$294K Sell
4,250
-3,466
-45% -$210K ﹤0.01% 2321
2019
Q3 		$801K Sell
7,716
-6,527
-46% -$616K ﹤0.01% 1907
2019
Q2 		$1.32M Sell
14,243
-1,485
-9% -$103K ﹤0.01% 1731
2019
Q1 		$1.44M Sell
15,728
-15,263
-49% -$1.06M ﹤0.01% 1703
2018
Q4 		$1.73M Sell
30,991
-1,730
-5% -$131K ﹤0.01% 1602
2018
Q3 		$3.9M Sell
32,721
-27
-0.1% -$3.13K ﹤0.01% 1485
2018
Q2 		$3.34M Buy
32,748
+20
+0.1% +$2.48K ﹤0.01% 1487
2018
Q1 		$4.25M Buy
32,728
+1,732
+6% +$189K ﹤0.01% 1453
2017
Q4 		$3.02M Buy
30,996
+130
+0.4% +$17.5K ﹤0.01% 1496
2017
Q3 		$4.54M Buy
+30,866
New +$5.8M ﹤0.01% 1452

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

T. Rowe Price Associates's SYRS Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 22,550 shares — an estimated $49K sold.

T. Rowe Price Associates first reported a position in SYRS in Q3 2017 and held it in 26 quarters. The position peaked at $4.54M in Q3 2017. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 22,550 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $49K.
  • T. Rowe Price Associates first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 26 quarters.
  • T. Rowe Price Associates's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.54M in Q3 2017.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.